133 related articles for article (PubMed ID: 30853393)
1. Optimal control of acute myeloid leukaemia.
Sharp JA; Browning AP; Mapder T; Burrage K; Simpson MJ
J Theor Biol; 2019 Jun; 470():30-42. PubMed ID: 30853393
[TBL] [Abstract][Full Text] [Related]
2. Designing combination therapies using multiple optimal controls.
Sharp JA; Browning AP; Mapder T; Baker CM; Burrage K; Simpson MJ
J Theor Biol; 2020 Jul; 497():110277. PubMed ID: 32294472
[TBL] [Abstract][Full Text] [Related]
3. TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia.
Kikushige Y; Akashi K
Ann N Y Acad Sci; 2012 Aug; 1266():118-23. PubMed ID: 22901263
[TBL] [Abstract][Full Text] [Related]
4. [The immunophenotypic analysis of CD7+ and (or) CD56+ acute myeloid leukemic stem cells and its applications in minimal residual disease detection].
Cao H; Wang YZ; Wu HH; Chang Y; Hao L; Chen SS; Huang XJ; Lu DP; Liu YR
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):23-8. PubMed ID: 18512311
[TBL] [Abstract][Full Text] [Related]
5. CD7 positive acute myeloid leukaemia: a subtype associated with cell immaturity.
Lo Coco F; De Rossi G; Pasqualetti D; Lopez M; Diverio D; Latagliata R; Fenu S; Mandelli F
Br J Haematol; 1989 Dec; 73(4):480-5. PubMed ID: 2482063
[TBL] [Abstract][Full Text] [Related]
6. Vim-2, candidate monoclonal antibody for purging autologous marrow grafts in acute myeloblastic leukaemia.
Delwel R; Bot F; Knapp W; Löwenberg B
Bone Marrow Transplant; 1987 Aug; 2(2):149-54. PubMed ID: 3332163
[TBL] [Abstract][Full Text] [Related]
7. Targeting of AML-leukemic stem cells with monoclonal antibodies.
Lee EM; Lock RB
Future Oncol; 2009 Nov; 5(9):1327-30. PubMed ID: 19903061
[No Abstract] [Full Text] [Related]
8. Use of rhG-CSF in the collection of peripheral blood stem cells for autologous blood stem cell transplantation in acute myeloblastic leukemia.
Jurado M; Delgado C; Moratalla A; Casero D; Oyonarte S; de Pablos JM
Bone Marrow Transplant; 1996 Oct; 18(4):821-2. PubMed ID: 8899205
[TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukaemia and the immune system: implications for immunotherapy.
Barrett AJ
Br J Haematol; 2020 Jan; 188(1):147-158. PubMed ID: 31782805
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells.
Majeti R
Oncogene; 2011 Mar; 30(9):1009-19. PubMed ID: 21076471
[TBL] [Abstract][Full Text] [Related]
11. Research on the clinical effect and in vitro study of HLA-mismatched hematopoietic stem cell infusion for acute myeloid leukemia.
Zhang R; Zhao F; Wang J
Hematology; 2015 Dec; 20(10):555-60. PubMed ID: 26067370
[TBL] [Abstract][Full Text] [Related]
12. Atg5-dependent autophagy contributes to the development of acute myeloid leukemia in an MLL-AF9-driven mouse model.
Liu Q; Chen L; Atkinson JM; Claxton DF; Wang HG
Cell Death Dis; 2016 Sep; 7(9):e2361. PubMed ID: 27607576
[TBL] [Abstract][Full Text] [Related]
13. Feedback regulation in a stem cell model with acute myeloid leukaemia.
Jiao J; Luo M; Wang R
BMC Syst Biol; 2018 Apr; 12(Suppl 4):43. PubMed ID: 29745850
[TBL] [Abstract][Full Text] [Related]
14. The nature of blast cells in myelodysplastic syndromes evolving to acute leukaemia.
San Miguel JF; González M; Cañizo MC; Anta JP; Hernández J; Ortega F; Borrasca L
Blut; 1986 Jun; 52(6):357-63. PubMed ID: 3459562
[TBL] [Abstract][Full Text] [Related]
15. [Expression of AC133 vs. CD34 in acute childhood leukemias].
Ebener U; Brinkmann A; Zotova V; Niegemann E; Wehner S
Klin Padiatr; 2000; 212(3):90-8. PubMed ID: 10916777
[TBL] [Abstract][Full Text] [Related]
16. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
17. Cellular Reprogramming Allows Generation of Autologous Hematopoietic Progenitors From AML Patients That Are Devoid of Patient-Specific Genomic Aberrations.
Salci KR; Lee JH; Laronde S; Dingwall S; Kushwah R; Fiebig-Comyn A; Leber B; Foley R; Dal Cin A; Bhatia M
Stem Cells; 2015 Jun; 33(6):1839-49. PubMed ID: 25764124
[TBL] [Abstract][Full Text] [Related]
18. Antigenic determinants on myeloid leukaemia colony-forming cells resemble those of normal myeloid progenitor cells and differ from those of circulating blast cells.
Robak T; Dowding C; Garewal G; Hibbin JA; Th'ng KH; Goldman JM
Br J Haematol; 1986 Sep; 64(1):133-48. PubMed ID: 2428394
[TBL] [Abstract][Full Text] [Related]
19. Positive selection for CD90 as a purging option in acute myeloid leukemia stem cell transplants.
Feller N; Kelder A; Westra G; Ossenkoppele GJ; Schuurhuis GJ
Cytometry B Clin Cytom; 2008 Jan; 74(1):9-16. PubMed ID: 18061946
[TBL] [Abstract][Full Text] [Related]
20. Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.
Davies JK; Hassan S; Sarker SJ; Besley C; Oakervee H; Smith M; Taussig D; Gribben JG; Cavenagh JD
Br J Haematol; 2018 Feb; 180(3):346-355. PubMed ID: 29076145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
